Prostate-specific antigen (PSA) testing, introduced in the 1990s, not only increased the incidence of clinically insignificant PCa (CSPCa, defined as Gleason score ≥ 3 + 4), but also led to an increased number of unnecessary biopsies. The gene discussed is KLK3; the disease is posterior cortical atrophy.